Literature DB >> 8960746

Familial meningocerebrovascular amyloidosis, Hungarian type, with mutant transthyretin (TTR Asp18Gly)

F Garzuly1, R Vidal, T Wisniewski, F Brittig, H Budka.   

Abstract

Amyloid deposits in leptomeningeal vessels, subarachnoid, subpial, and subependymal cerebrospinal regions, spinal ganglia, peripheral nerves, and some internal organs (predominantly heart and kidney) characterize a dominantly inherited disease in a Hungarian family. We found four definitely and three probably affected members in this family of 56 persons in four generations. Clinical features in all definitely diseased patients include disturbance of memory, psychomotor deceleration, ataxia, and hearing loss. In most patients there was temporary disorientation, migraine-like headache with vomiting, and tremor. Some patients had nystagmus, pyramidal signs with spastic paraparesis, hallucinations, urinary retention, and obstipation. Single patients had facial tics and sleep disorders. Progressive visual disturbance and clinically manifest polyneuropathy were absent. CSF protein was markedly elevated in all patients. CT showed characteristic symmetric calcification along the sylvian fissure; MRI after contrast administration showed prominent enhancement at the surface of the sylvian fissures, brainstem, and cerebellum. Autopsy data was available in three definitely affected patients and in one unaffected family member. Immunohistochemistry identified the amyloid deposits as of the AF (transthyretin, TTR) type; DNA studies revealed a novel TTR missense mutation at codon 18 (TTR Asp18Gly). According to clinical features, pathologic alterations, and molecular studies, this disease is a novel type of systemic familial amyloidosis with disease manifestation clinically restricted to the CNS. It is similar to the oculoleptomeningeal amyloidoses but can be clinically diagnosed by characteristic CTs and the absence of progressive visual impairment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8960746     DOI: 10.1212/wnl.47.6.1562

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  14 in total

Review 1.  Current and future treatment of amyloid diseases.

Authors:  M Ankarcrona; B Winblad; C Monteiro; C Fearns; E T Powers; J Johansson; G T Westermark; J Presto; B-G Ericzon; J W Kelly
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

2.  Age-dependent cognitive dysfunction in untreated hereditary transthyretin amyloidosis.

Authors:  Ana Martins da Silva; Sara Cavaco; Joana Fernandes; Raquel Samões; Cristina Alves; Márcio Cardoso; Jeffery W Kelly; Cecília Monteiro; Teresa Coelho
Journal:  J Neurol       Date:  2017-12-05       Impact factor: 4.849

3.  FRET studies of various conformational states adopted by transthyretin.

Authors:  Seyyed Abolghasem Ghadami; Francesco Bemporad; Benedetta Maria Sala; Guido Tiana; Stefano Ricagno; Fabrizio Chiti
Journal:  Cell Mol Life Sci       Date:  2017-05-06       Impact factor: 9.261

4.  The identification of a transthyretin variant p.D38G in a Chinese family with early-onset leptomeningeal amyloidosis.

Authors:  Kuan Fan; Haixia Zhu; Hongbo Xu; Ping Mao; Lamei Yuan; Hao Deng
Journal:  J Neurol       Date:  2018-11-23       Impact factor: 4.849

Review 5.  Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out.

Authors:  John J Chen; Joseph C Genereux; R Luke Wiseman
Journal:  IUBMB Life       Date:  2015-05-26       Impact factor: 3.885

Review 6.  Cerebral amyloidosis: amyloid subunits, mutants and phenotypes.

Authors:  A Rostagno; J L Holton; T Lashley; T Revesz; Jorge Ghiso
Journal:  Cell Mol Life Sci       Date:  2009-11-07       Impact factor: 9.261

7.  Subarachnoid hemosiderosis and superficial cortical hemosiderosis in cerebral amyloid angiopathy.

Authors:  J Linn; J Herms; M Dichgans; H Brückmann; G Fesl; T Freilinger; M Wiesmann
Journal:  AJNR Am J Neuroradiol       Date:  2007-10-18       Impact factor: 3.825

Review 8.  Transthyretin and the brain re-visited: is neuronal synthesis of transthyretin protective in Alzheimer's disease?

Authors:  Xinyi Li; Joel N Buxbaum
Journal:  Mol Neurodegener       Date:  2011-11-23       Impact factor: 14.195

9.  Probing conformational changes of monomeric transthyretin with second derivative fluorescence.

Authors:  Denisa Jazaj; Seyyed Abolghasem Ghadami; Francesco Bemporad; Fabrizio Chiti
Journal:  Sci Rep       Date:  2019-07-29       Impact factor: 4.379

10.  Oculoleptomeningeal Amyloidosis associated with transthyretin Leu12Pro in an African patient.

Authors:  P McColgan; S Viegas; S Gandhi; K Bull; R Tudor; F Sheikh; J Pinney; M Fontana; D Rowczenio; J D Gillmore; J A Gilbertson; C J Whelan; S Shah; Z Jaunmuktane; J L Holton; J M Schott; D J Werring; P N Hawkins; M M Reilly
Journal:  J Neurol       Date:  2014-12-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.